A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Clinical trial NCT06954246 · RECRUITING
Trial details
- NCT number
- NCT06954246
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-04
- Primary completion
- 2027-05-01
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.